X4 Pharmaceuticals Lands $150M Debt Facility With K2 HealthVentures
X4 Pharmaceuticals secured up to $150 million in senior debt financing from K2 HealthVentures, retiring its prior loan and extending its financial runway.
X4 Pharmaceuticals has closed a senior debt facility worth up to $150 million with K2 HealthVentures, the company announced, simultaneously retiring its existing loan obligations and positioning itself with expanded capital for corporate and commercial operations.
The new arrangement replaces a prior loan facility, eliminating that debt burden while opening access to fresh funding the company says will support both business development and commercial activities. The structure of the deal — providing tiered access to capital rather than a single lump sum — gives X4 financial flexibility to draw funds as needed.
Read more Aetna Reports 69% of Medicare Advantage Members in Top-Rated Plans →
The financing also underpins X4's clinical development timeline. The company expects to complete enrollment in its Phase 3 4WARD clinical trial by the end of 2026, with topline results anticipated in the first half of 2028. The 4WARD trial represents a pivotal program for the company, and securing long-term capital is critical to sustaining operations through what is expected to be a multi-year data readout period.
For smaller biopharmaceutical companies, non-dilutive debt financing from specialized lenders such as K2 HealthVentures has become an increasingly common alternative to equity raises, allowing firms to preserve shareholder value while funding operations and late-stage trials. X4's ability to secure $150 million under a senior facility suggests lender confidence in the company's clinical and commercial trajectory.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
